Northern Trust Corp Purchases 22,377 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Northern Trust Corp grew its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 51.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,783 shares of the biopharmaceutical company's stock after acquiring an additional 22,377 shares during the quarter. Northern Trust Corp owned 0.09% of Xenon Pharmaceuticals worth $2,579,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Quarry LP acquired a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at $78,000. Blue Trust Inc. raised its stake in shares of Xenon Pharmaceuticals by 140.3% in the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock valued at $95,000 after buying an additional 1,414 shares in the last quarter. Avior Wealth Management LLC acquired a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at $101,000. KBC Group NV lifted its holdings in shares of Xenon Pharmaceuticals by 39.8% during the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 780 shares during the period. Finally, Magnetar Financial LLC acquired a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at about $210,000. Institutional investors own 95.45% of the company's stock.

Xenon Pharmaceuticals Price Performance

Shares of XENE stock traded down $0.29 during trading hours on Tuesday, reaching $29.46. 1,064,811 shares of the company were exchanged, compared to its average volume of 525,847. Xenon Pharmaceuticals Inc. has a fifty-two week low of $26.74 and a fifty-two week high of $46.00. The stock's fifty day moving average is $33.52 and its two-hundred day moving average is $37.35. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -10.45 and a beta of 1.21.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.07. The company had revenue of $7.50 million during the quarter, compared to the consensus estimate of $1.64 million. During the same quarter last year, the firm earned ($0.62) EPS. On average, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Chardan Capital reissued a "buy" rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. Needham & Company LLC decreased their price target on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Wall Street Zen cut Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Finally, The Goldman Sachs Group dropped their price objective on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $54.82.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.